[This corrects the article DOI: 10.1038/s41413-019-0072-9.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118404 | PMC |
| http://dx.doi.org/10.1038/s41413-020-0092-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
The Jackson Laboratory, Bar Harbor, ME, USA.
Background: Determining the precise genetic mechanisms that contribute to LOAD, both in coding and noncoding variants, will enable a deeper understanding of pathogenesis and advance preclinical models for the testing of targeted therapeutics.
Methods: We have introduced candidate genetic variants in the EPHA1, BIN1, CD2AP, SCIMP, KLOTHO, PTK2B, ADAMTS4, IL1RAP, IL34, and PTPRB loci into a sensitized mouse model already harboring humanized amyloid-beta, APOE4, and Trem2.R47H alleles knocked in to a C57BL/6J background.
[Peripheral ulcerative keratitis associated with dupilumab: a case report].
Zhonghua Yan Ke Za Zhi
January 2025
Department of Ophthalmology,Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing100730,China.
Article Synopsis
- A 68-year-old male experienced irritation in both eyes, including symptoms like photophobia and tearing, after starting dupilumab for severe atopic dermatitis.
- He had a specific corneal ulcer in the right eye and a pannus in the left eye, but tests ruled out infections.
- Treatment with eye drops led to significant improvement, and follow-up revealed healing of the corneal lesions and improved vision.
Correction: Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE.
Cell Commun Signal
December 2024
Department of Pharmacology, Physiology & Neuroscience New Jersey Medical School, The State University of New Jersey, Rutgers, Newark, NJ, USA.
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Replacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibody.
BMC Infect Dis
December 2024
Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
Background: Virus neutralising antibodies in serum are considered key correlates of protection for vaccines and monoclonal antibodies against respiratory syncytial virus (RSV). RSM01 is a novel, highly-potent, half-life-extended and fully-human monoclonal antibody candidate targeting the RSV prefusion F protein. Currently in Phase 1 development, RSM01 is primarily being developed to potentially provide an effective and affordable RSV prevention strategy in low- and middle-income countries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!